Anti-SARS-CoV-2 receptor binding domain antibodies after the second dose of Sinovac and AstraZeneca vaccination.

Marisca Evalina Gondokesumo Anita Purnamayanti Puri Safitri Hanum Winnie Nirmala Santosa Ardyan Prima Wardhana Christina Avanti

Published in: Clinical and experimental vaccine research (2023)

Sinovac induced more significant titers of anti-SRBD IgG 1 month after the second dose but generated fewer AEFIs. In contrast, AstraZeneca generated more AEFIs, in mild to moderate severity, but provided lower levels of anti-SRBD IgG.

Keyphrases

sars cov
high glucose
magnetic resonance imaging
diabetic rats
drug induced
oxidative stress
endothelial cells